secwatch.observer — SEC 8-K summary
======================================

Issuer:     Turn Therapeutics Inc. (TTRX)
CIK:        0002023016
Form:       8-K
Filed at:   2026-02-09T23:59:59+00:00
Accession:  0001213900-26-013490
Event type: other_material
Sentiment:  neutral
Materiality: 0.20
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Turn Therapeutics announces presentations at TD Cowen and Oppenheimer healthcare conferences
--------------------------------------------------------------------------------

- CEO Brad Burnam to present at 46th Annual TD Cowen Healthcare Conference in Boston on March 2, 2026.
- Also presenting virtually at 36th Annual Oppenheimer Healthcare Life Sciences Conference on February 25, 2026.
- Company to provide update on Phase 2 trial of GX-03 for moderate-to-severe atopic dermatitis.
- Updated investor presentation posted on company website on February 9, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2023016/000121390026013490/0001213900-26-013490-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2023016/000121390026013490/ea0275934-8k_turn.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-013490

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer